ImmuCell Corp. (NASDAQ:ICCC) Director David Scott Tomsche bought 4,000 shares of ImmuCell Corp. stock in a transaction that occurred on Monday, November 7th. The stock was bought at an average cost of $5.19 per share, with a total value of $20,760.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ImmuCell Corp. (NASDAQ:ICCC) opened at 5.31 on Thursday. ImmuCell Corp. has a 1-year low of $4.99 and a 1-year high of $8.29. The firm has a market capitalization of $22.19 million, a P/E ratio of 17.82 and a beta of 0.81. The stock’s 50 day moving average is $6.80 and its 200-day moving average is $6.94.

ImmuCell Corp. Company Profile

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

5 Day Chart for NASDAQ:ICCC

Receive News & Stock Ratings for ImmuCell Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Corp. and related stocks with our FREE daily email newsletter.